patent.fyi
Applications  /  US 2026/0355190
United States Patent Application Publication

US 2026/0355190 A1

Published
Nov 12, 2026
Filed
Mar 30, 2026
Earliest date on the face
Apr 1, 2025
Classification
A61K 31/5025
First published here
Nov 19, 2026

Generated automatically. Not reviewed by a person. Not legal advice or an opinion.

Section 1 · machine-generated

What if?

Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.

1.2Hydroxyethyl at the tether position

What ifWhat if R′ is a hydroxyethyl group?
Claim language“optionally substituted haloalkyl”

A two-carbon chain projects from the attachment point and ends in a hydroxyl group. The terminal hydroxyl donates and accepts hydrogen bonds at the exposed end of the chain.

1.3Cyclohexyl at the R position

What ifWhat if a cyclohexyl group supplies the ring-shaped bulk at R?
Claim language“optionally substituted heterocyclyl”

Six saturated carbon atoms form the ring, which connects to the core through one ring carbon. The cyclohexyl group adopts a chair conformation and presents a hydrophobic surface.

1.5Cyano at the ring position

What ifWhat if a cyano group at R2 supplies a compact polar substituent?
Claim language“optionally substituted alkoxy”

The ring bonds directly to the carbon of the C≡N group. The linear nitrile provides a permanent dipole and a hydrogen-bond acceptor at its terminal nitrogen.

1.7Geminal fluorines at the linker

What ifWhat if two fluorines occupy the R6 and R7 positions on the same linker carbon?
Claim language“a carbonyl group”

The linker carbon forms two carbon–fluorine single bonds and retains its two bonds to the surrounding framework. The fluorines withdraw electron density through the single bonds, and the linker carbon has tetrahedral geometry.

1.12Nicotinic agonist as partner active

What ifWhat if the additional active agent is a nematode nicotinic receptor agonist from the imidazothiazole class?
Claim language“a macrocyclic lactone”

The imidazothiazole activates nicotinic acetylcholine receptors on susceptible nematode muscle. Sustained depolarization causes spastic paralysis, allowing intestinal motility to expel the worms.

Section 2 · machine-generated

Variations

Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.

Parameter or scale variation

Combination capsules in three fill sizes

Separate granulate batches contain the first anthelmintic and the macrocyclic lactone at fixed active concentrations. A dual-hopper filler dispenses 50 mg of each granulate into the smallest capsule, 100 mg of each into the middle capsule, and 200 mg of each into the largest capsule. The resulting 100 mg, 200 mg, and 400 mg total fill masses preserve the active mass ratio across all three sizes.

Combination with existing systems

Dual cartridge dispenser with animal identification

A livestock handling station connects an ear-tag reader, a weigh platform, and an oral dispenser with two replaceable cartridges. One cartridge holds the first anthelmintic suspension and the other holds a macrocyclic lactone suspension, each with a dedicated metering pump. A controller matches the tag and measured weight to a stored dosing table, then drives both pumps to deliver their metered volumes through separate channels in a single applicator tip.

Separate flow cells for dissolution testing

A flow-through dissolution apparatus holds the first anthelmintic granulate and the second active granulate in separate cells supplied by a common temperature-controlled medium reservoir. Each cell has its own metered inlet and timed fraction collector, which preserves the release profile of each granulate. Liquid chromatography measures the active concentration in each fraction, and the pressure and flow records identify interruptions during the run.

Automated or data-driven variant

Automated strength checks for paired granulates

An at-line near-infrared spectrometer measures each granulate stream before a capsule filler combines the first anthelmintic with the second active. Separate calibration models use chromatographic assay results to relate each granulate spectrum to its active concentration. The filling controller combines the estimated concentrations with the measured fill masses, then diverts capsules when the estimated content of either active falls outside its configured band.

Specific version of a part

Methyl and hydrogen on nitrogen

Ra is methyl and Rb is hydrogen. The resulting —NHCH₃ group attaches to the core through nitrogen and retains one nitrogen–hydrogen bond.

Methylsulfonyl at one ring position

One R5 position carries —S(=O)₂CH₃ with p set to 2. The ring connects directly to sulfur, and the two sulfonyl oxygens act as hydrogen-bond acceptors.

Methyl on the linker nitrogen

R8 is methyl in an N—R8 unit. The nitrogen bonds to the two adjacent framework atoms and to the methyl carbon.

Methoxy at the R10 position

R10 is methoxy, —OCH₃. The oxygen bonds directly to the framework and serves as a hydrogen-bond acceptor.

Section 3 · quoted from USPTO records

Other work

Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.

Document AUS 2007/0232621 A1
Published
Oct 4, 2007
Filed
Jan 25, 2007
Class
A61K 31/34
Document BUS 7,557,116 B2
Published
Jul 7, 2009
Filed
Nov 5, 2003
Class
A01N 43/54
Claim 1
Document A
Document B
1.1a first antiparasitic active agent in the combination is an anthelmintic compound of Formula (IA), Formula (IB) or Formula (IC), or a combination thereof: or salts thereof
1.2wherein: L is L1 or L2: R′ is hydrogen, optionally substituted alkyl or optionally substituted haloalkyl
1.3R is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted heterocyclyl or —NRaRb
“Cyclic” and “cycloalkyl” refer to a non-aromatic mono- or multicyclic ring system of about 3 to about 10 carbon atoms, e.g., 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. The cycloalkyl group can be optionally partially unsaturated.
A · US 2007/0232621 A1 · ¶ 126
1.4wherein Ra and Rb are independently H or optionally substituted alkyl
The aryl group can be optionally substituted (a “substituted aryl”) with one or more aryl group substituents, which can be the same or different, wherein “aryl group substituent” includes alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, an
A · US 2007/0232621 A1 · ¶ 111
R1 is selected from the group of H, OH, Cl, O-Alkyl, NH.sub.2, NH-Alkyl, NH-Ar, N(Alkyl).sub.2, SH, S-Alkyl, S-Ar, S-Hetaryl;
B · US 7,557,116 B2 · ¶ 10
1.5R1, R2, R3 and R4 are independently hydrogen, cyano, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy
wherein: p and q are each independently an integer from 0 to 8; m is an integer from 0 to 4; n is an integer from 0 to 4; each Z, A, and Y is independently selected from the group consisting of N and CR4, wherein R4 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl; each R1, R2 and R5 is independently selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl
A · US 2007/0232621 A1 · ¶ 88
1.6R5 is independently each occurrence, hydrogen, halogen, cyano, optionally substituted alkyl, optionally substituted alkoxy, optionally substituted alkylcarbonyl, optionally substituted alkoxycarbonyl, optionally substituted aminocarbonyl, optionally substituted alkylaminocarbonyl, optionally substituted dialkylaminocarbonyl, optionally substituted alkylcarbonyloxy, optionally substituted alkylcarbonylamino, —SOp(optionally substituted alkyl), —SOp(optionally substituted haloalkyl)
The aryl group can be optionally substituted (a “substituted aryl”) with one or more aryl group substituents, which can be the same or different, wherein “aryl group substituent” includes alkyl, substituted alkyl, aryl, substituted aryl, aralkyl, hydroxyl, alkoxyl, aryloxyl, aralkyloxyl, carboxyl, acyl, halo, nitro, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, acyloxyl, acylamino, aroylamino, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylthio, alkylthio, alkylene, an
A · US 2007/0232621 A1 · ¶ 111
R2=C6H5 or substituted phenyl: C6H4X′ (where X′=Alkyl, Halogen, NO2, O-Alkyl, N(Alkyl)2, CN, S-Alkyl); or disubstituted; or trisubstituted phenyl;
B · US 7,557,116 B2 · claim 1
1.7R6 and R7 are independently hydrogen, halogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted alkoxy, or R6 together with R7 for a carbonyl group (C═O)
1.8R8 is hydrogen or optionally substituted alkyl
1.9R9 is hydrogen, halogen or optionally substituted alkyl
1.10R10 is cyano, halogen, optionally substituted alkyl or optionally substituted alkoxy
R2=C6H5 or substituted phenyl: C6H4X′ (where X′=Alkyl, Halogen, NO2, O-Alkyl, N(Alkyl)2, CN, S-Alkyl); or disubstituted; or trisubstituted phenyl;
B · US 7,557,116 B2 · claim 1
1.11Q is C, C—R9 or N
1.12X is O, S or N—R′ Y1, Y2, Y3 and Y4 are each independently N or —CR5— W is CR6, CR6R7, O, SOp, N or N—R8, or W is absent W1 is CR6, CR6R7, O, SOp, N or N—R8 Z is CR6, CR6R7, O, SOp, N or N—R8, and wherein at most three of Y1, Y2, Y3 and Y4 are N m is 0, 1, 2, 3, 4 or 5 p is independently in each occurrence is 0, 1, or 2 the dashed bonds ()signifies a single or double bond wherein “optionally substituted” indicates that the group recited may be optionally substituted with halogen (independently chloro, fluoro, bromo or iodo), hydroxyl, thiol, oxo (C═O), C1-C6-alkyl, C1-C6-haloalkyl, C3-C8-cycloalkyl, C1-C6-alkoxy, C1-C6-haloalkoxy, —S(O)p(C1-C6-alkyl) or —S(O)p(C1-C6-haloalkyl) where p is 0, 1 or 2, carboxyl, acetyl, C1-C6-alkylcarbonyl, C1-C6-haloalkylcarbonyl, C1-C6-alkoxycarbonyl, C1-C6-haloalkoxycarbonyl, aminocarbonyl, C1-C6-alkylaminocarbonyl, di-C1-C6-alkylaminocarbonyl, C1-C6-haloalkylaminocarbonyl, di-C1-C6-haloalkylaminocarbonyl, amino, C1-C6-alkylamino, di-C1-C6-alkylamino, nitro, cyano, R3Si— or R3SiO— where R is C1-C6-alkyl, C1-C6-haloalkyl or phenyl, SF5, phenyl, naphthyl, 5- to 10-membered heteroaryl containing from one to three N, O, Si or S heteroatoms 3- to 10-membered heterocyclyl containing from one to three N, O, Si or S heteroatoms the second or more additional antiparasitic active agent(s) in the combination is a macrocyclic lactone, an isoxazoline, praziquantel or pyrantel, or a combination thereof.
wherein: p and q are each independently an integer from 0 to 8; m is an integer from 0 to 4; n is an integer from 0 to 4; each Z, A, and Y is independently selected from the group consisting of N and CR4, wherein R4 is selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl, alkoxyl, aryl, substituted aryl, and aryloxyl; each R1, R2 and R5 is independently selected from the group consisting of H, hydroxyl, halo, nitro, alkyl, substituted alkyl
A · US 2007/0232621 A1 · ¶ 88

An empty cell means only that no passage was reproduced there.

Statements in these documents
Thus, there continues to be a need for improvement in the art for additional compounds having desirable antimicrobial activity, whether against the representative pathogens referenced above or against other pathogens.
A · US 2007/0232621 A1 · ¶ 60
The presently disclosed subject matter relates to methods for combating microbial infections with novel dicationic terphenyl compounds and their aza analogues, processes for synthesizing novel dicationic terphenyl compounds and their aza analogues, and the novel dicationic terphenyl compounds and their aza analogues themselves.
A · US 2007/0232621 A1 · ¶ 2
Derivatives of 5H-pyrano[2,3-d: 6,5-d′]dipyrimidine are the most closely claimed compounds taken as prototypes in the present invention; however, the prototype compounds are shown to possess a limited spectrum of antiviral and antibacterial activity.
B · US 7,557,116 B2 · ¶ 7
The derivatives in the present invention, however, posses antibacterial, antiviral and immunomodulating effects.
B · US 7,557,116 B2 · ¶ 7
Cite aspatent.fyi, US 2026/0355190 A1, claim 1, first published 2026-11-19T09:07:06-05:00, https://patent.fyi/US20260355190/, SHA-256 5ce60e56d680294da594e2c2f6e52d0ffe15dce451c514972dfccf6d63920d61
First published
Permanent addresshttps://patent.fyi/US20260355190/
Content fingerprint (SHA-256)5ce60e56d680294da594e2c2f6e52d0ffe15dce451c514972dfccf6d63920d61
Methodv2026-11-18.2 · automated, not reviewed by a person
Correctionscorrections@patent.fyi